EUVIMEDEUVIMED entdecken
Open Access

Bayesian design of clinical trials using joint models for longitudinal and time-to-event data

Jiawei Xu, Matthew A Psioda, Joseph G Ibrahim

Biostatistics · 13.04.2022 · 23 (2) · 591-608

DOI: 10.1093/biostatistics/kxaa044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biostatistics, online erschienen am 06.11.2020. Verfasst von Jiawei Xu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA. Hauptthemen laut MEDLINE: Models, Statistical, Research Design. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Joint models for longitudinal and time-to-event data are increasingly used for the analysis of clinical trial data. However, few methods have been proposed for designing clinical trials using these models. In this article, we develop a Bayesian clinical trial design methodology focused on evaluating the treatment’s effect on the time-to-event endpoint using a flexible trajectory joint model. By incorporating the longitudinal outcome trajectory into the hazard model for the time-to-event endpoint, the joint modeling framework allows for non-proportional hazards (e.g., an increasing hazard ratio over time). Inference for the time-to-event endpoint is based on an average of a time-varying hazard ratio which can be decomposed according to the treatment’s direct effect on the time-to-event endpoint and its indirect effect, mediated through the longitudinal outcome. We propose an approach for sample size determination for a trial such that the design has high power and a well-controlled type I error rate with both operating characteristics defined from a Bayesian perspective. We demonstrate the methodology by designing a breast cancer clinical trial with a primary time-to-event endpoint and where predictive longitudinal outcome measures are also collected periodically during follow-up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Models, StatisticalResearch DesignBayes TheoremHumansLongitudinal StudiesProportional Hazards ModelsSample Size

Stichwörter der Autor:innen

Bayesian designClinical trialsJoint modelsSampling prior

Autor:innen und Institutionen

  • Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • National Institutes of Health
  • NIH

Zitieren

APA

Xu, J., Psioda, M. A., & Ibrahim, J. G. (2022). Bayesian design of clinical trials using joint models for longitudinal and time-to-event data. Biostatistics, 23(2), 591-608. https://doi.org/10.1093/biostatistics/kxaa044

Vancouver

Xu J, Psioda MA, Ibrahim JG. Bayesian design of clinical trials using joint models for longitudinal and time-to-event data. Biostatistics. 2022;23(2):591-608. doi:10.1093/biostatistics/kxaa044

BibTeX
@article{Xu2022,
  author = {Xu, Jiawei and Psioda, Matthew A and Ibrahim, Joseph G},
  title = {Bayesian design of clinical trials using joint models for longitudinal and time-to-event data},
  journal = {Biostatistics},
  year = {2022},
  volume = {23},
  number = {2},
  pages = {591--608},
  doi = {10.1093/biostatistics/kxaa044}
}
Kostenlos starten →